<DOC>
	<DOCNO>NCT01192763</DOCNO>
	<brief_summary>This phase I trial study side effect RO4929097 surgery treat patient pancreatic cancer . RO4929097 may stop growth tumor cell block enzymes need cell growth . Giving RO4929097 surgery may make tumor small reduce amount normal tissue need remove .</brief_summary>
	<brief_title>RO4929097 Before Surgery Treating Patients With Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate effect neoadjuvant gamma-secretase inhibitor RO4929097 Notch inhibition via interrogation Hes-1 expression patient pancreatic cancer . SECONDARY OBJECTIVES : I . To evaluate effect regimen pancreatic cancer stem cell self-renewal tumorigenesis compare pancreatic stem cell control ( patient receive treatment ) . II . To evaluate safety regimen patient . OUTLINE : This multicenter study . Patients receive oral gamma-secretase inhibitor RO4929097 day 1-3 8-10 absence disease progression unacceptable toxicity . Beginning 7 day completion gamma-secretase inhibitor RO4929097 , patient undergo complete resection comprise pancreaticoduodenectomy , distal pancreatectomy , total pancreatectomy base anatomic location cancer . Tumor tissue biopsy surgery blood sample collect periodically pharmacodynamic study . After completion study therapy , patient follow every 6 month 1 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm pancreatic adenocarcinoma T13 , N01 , M0 disease Surgically resectable disease confirm surgeon experience pancreatic surgery No borderline resectable disease define follow : Tumors severe unilateral bilateral SMV/portal involvement impingement Abutment ( ) encasement hepatic artery SMA celiac encasement ( ) presence SMV occlusion tumor No metastatic disease ECOG performance status 01 Life expectancy &gt; 6 month WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 2 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 2 mg/dL Calcium , magnesium , phosphorous , potassium normal Negative pregnancy test Not pregnant nursing Fertile patient must use effective barriermethod contraception 4 week , , ≥ 12 month completion treatment Able swallow tablet No malabsorption syndrome condition would interfere intestinal absorption No history allergic reaction attribute compound similar chemical biologic composition gammasecretase inhibitor RO4929097 agent use study No uncontrolled hypocalcemia , hypomagnesemia , hyponatremia , hypophosphatemia , hypokalemia despite adequate electrolyte supplementation Grade 1 hyponatremia sodium ≤ 131 mg/dL permissible No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia chronic Stable atrial fibrillation Psychiatric illness/social situation would limit compliance study requirement No baseline QTcF &gt; 450 msec ( male ) QTcF &gt; 470 msec ( female ) Patients prior cancer evidence active cancer exclude study Patients prior cancer permit enter study long document evidence active malignancy No uncontrolled electrolyte abnormality include hypocalcemia , hypomagnesemia , hypokalemia No symptomatic congestive heart failure , unstable angina pectoris , history torsades de pointes significant cardiac arrhythmia No requirement antiarrhythmic medication know prolong QTc No concurrent anticancer agent therapy Recovered &lt; grade 2 toxicity relate prior therapy No prior chemotherapy radiotherapy pancreatic cancer No concurrent investigational agent No concurrent medication narrow therapeutic index metabolize cytochrome P450 ( CYP450 ) , include warfarin sodium ( Coumadin® ) , ketoconazole , grapefruit juice No concurrent strong inducer inhibitor CYP3A4 No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>